StockData
Apimeds Pharmaceuticals US, Inc. logo

Apimeds Pharmaceuticals US, Inc. (APUS) stock

APUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 2/30
$1.89−0.06 (-3.08%)

Close on Nov 18, 2026Market cap $2.85MP/E –Yield –

Apimeds Pharmaceuticals US free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Apimeds Pharmaceuticals US's free cash flow for the twelve months ending Sep 30, 2026 was -$11.80M. For fiscal 2025 it was -$8.98M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$8.98M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$218.62K–
Q2 FY2026Jun 30, 2026-$5.67M–
Q1 FY2026Mar 31, 2026-$2.08M–
Q4 FY2025Dec 31, 2025-$3.84M–
Q3 FY2025Sep 30, 2025-$1.75M–

More Apimeds Pharmaceuticals US figures

See a number that looks wrong?